Read by QxMD icon Read

Relapsed diffuse large B cell non hodgkin lymphoma

Ranjana H Advani, Daniel Lebovic, Andy Chen, Mark Brunvand, Andre Goy, Julie E Chang, Ephraim Hochberg, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Priya Agarwal, Randall Dere, Hsin-Ju Hsieh, Surai Jones, Yu-Waye Chu, Bruce D Cheson
PURPOSE: Pinatuzumab vedotin is an antibody-drug conjugate with the potent antimicrotubule agent monomethyl auristatin E (MMAE) conjugated to an anti-CD22 antibody via a protease-cleavable linker. This Phase I study determined its recommended Phase II dose (RP2D) and evaluated its safety, tolerability, and anti-tumor activity alone and with rituximab in relapsed/refractory (r/r) non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). EXPERIMENTAL DESIGN: Patients received escalating doses of pinatuzumab vedotin every 21 days...
September 6, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Ping Chen, Maoqing Jiang, Yuanwei Lin, Xianwang Ye, Xinzhong Ruan, Qiuli Huang
Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma occurring in various sites, but rarely involving the ureters. Primary DLBCL is a rare entity. Imaging studies in a 82-year-old male patient revealed left hydronephrosis and an area of nodular soft tissue density in the upper ureteral wall. On enhanced computed tomography scans, the lesion exhibited early enhancement. As the lesion was considered to be malignant, a left nephroureterectomy was performed for the purpose of pathological diagnosis...
September 2016: Molecular and Clinical Oncology
T Xu, J Chen, Z M Jin, M Miao, C C Fu, H Y Qiu, X W Tang, Y Han, A N Sun, D P Wu
OBJECTIVE: To explore the efficacy and safety of haploidentical hematopoietic stem cell transplantation (Haplo- HSCT) for refractory, relapsed or highly aggressive non- Hodgkin lymphoma (NHL) patients. METHODS: A total of 26 patients with refractory, relapsed or highly aggressive NHL who received Haplo- HSCT from Jan. 2004 to Mar. 2015 were analyzed retrospectively. RESULTS: Of them, 4 patients had diffuse large B-cell lymphoma (DLBCL), 1 had follicular lymphoma, 5 had B-lymphoblastic lymphoma/leukemia, 9 had T- lymphoblastic lymphoma/leukemia, 1 patient anaplastic large cell lymphoma (ALK-negative), 5 had peripheral T-cell lymphoma (NOS), and 1 had NK/T-cell lymphoma...
August 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Jozef Malysz, Patrick Erdman, Jeremy Klapper, Junjia Zhu, Michael Creer, Michael G Bayerl
BACKGROUND: US Food and Drug Administration approval of brentuximab vedotin for treatment of CD30-positive relapsed/refractory lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma, initiated significant interest in researching CD30 expression in other therapy-resistant or relapsed lymphomas. We evaluated CD30 expression in 116 cases of aggressive B-cell lymphomas diagnosed at Penn State Milton S. Hershey Medical Center between 2000 and 2012 with the purpose of assessing the benefit of treatment with brentuximab...
August 2016: Clinical Lymphoma, Myeloma & Leukemia
Natalie Galanina, Jagoda Jasielec, David Peace, Sonali M Smith, Chadi Nabhan
No abstract text is available yet for this article.
July 14, 2016: Leukemia & Lymphoma
Marta Pillon, Lara Mussolin, Elisa Carraro, Valentino Conter, Maurizio Aricò, Luciana Vinti, Alberto Garaventa, Matilde Piglione, Salvatore Buffardi, Alessandra Sala, Nicola Santoro, Luca Lo Nigro, Rossella Mura, Annalisa Tondo, Fiorina Casale, Piero Farruggia, Paolo Pierani, Simone Cesaro, Emanuele S G d'Amore, Giuseppe Basso
Burkitt lymphoma (BL) and Diffuse Large B-Cell Lymphoma (DLBCL) account for most cases of non-Hodgkin lymphoma (NHL) in childhood. We report the clinical characteristics, outcome and prognostic factors in children with BL or DLBCL treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) LNH-97 protocol. Patients aged up to 18 years that were newly diagnosed with BL/DLBCL were included in the study. Therapy consisted of pre-phase followed by 2-6 high-dose chemotherapy courses tailored according to lactate dehydrogenase (LDH) value and disease stage...
July 8, 2016: British Journal of Haematology
Norbert Schmitz, Samira Zeynalova, Maike Nickelsen, Roopesh Kansara, Diego Villa, Laurie H Sehn, Bertram Glass, David W Scott, Randy D Gascoyne, Joseph M Connors, Marita Ziepert, Michael Pfreundschuh, Markus Loeffler, Kerry J Savage
PURPOSE: To develop and validate a risk score for relapse in the CNS in patients with diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: A total of 2,164 patients (18 to 80 years old) with aggressive B-cell lymphomas (80% DLBCL) treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy, who were enrolled in studies from the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera International Trial, were analyzed for occurrence of relapse/progression in the CNS...
September 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Melinda Paksi, Judit Demeter, Péter Szabó
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL). Although this lymphoma is curable, 40% of patients with DLBCL will die of relapsed or refractory disease. 18F-Fluoro-deoxyglucose positron emission tomography (FDG-PET) is a noninvasive, 3-dimensional, functional imaging modality. When combined with the anatomical imaging tool computed tomography (CT), PET/CT can differentiate among others necrotic masses and viable tumors. PET scan has become a basic clinical tool for staging and response assessment in aggressive lymphomas, such as DLBCL...
June 6, 2016: Magyar Onkologia
Naoya Ishibashi, Masaharu Hata, Takao Mochizuki, Kogi Ogawa, Hiroaki Sugiura, Yoshinori Takekawa, Toshiya Maebayashi, Takuya Aizawa, Masakuni Sakaguchi, Osamu Abe
Primary breast lymphoma is a rare type of non-Hodgkin lymphoma and usually affects women, although a few cases have been reported in men. Chemotherapy and radiation therapy, or a combination of both, are frequently administered for treatment of primary breast lymphoma, as local control by surgical resection is poor. No standard therapy has been established, and the optimal radiation dose and irradiation field for male patients are unknown. The present report describes a 75-year-old man with bilateral cirrhosis-induced gynecomastia who was diagnosed with primary breast lymphoma; specifically, diffuse large B-cell lymphoma...
October 2016: International Journal of Hematology
Eri Matsuki, Anas Younes
Treatment for relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphoma remains challenging. The introduction of rituximab to B cell non-Hodgkin lymphoma (B-NHL) treatment significantly improved patients' response rate and survival; however, approximately one third of patients with diffuse large B cell lymphoma, the most common B-NHL subtype, still have a relapse or become refractory after first-line therapy. More recently, antibody therapies and small-molecule inhibitors were approved for treating R/R lymphomas; these agents include brentuximab vedotin, ibrutinib, and idelalisib...
June 2016: Current Treatment Options in Oncology
Medikonda Suresh Kumar, Ashalata Gannepalli, Anuradha Chandragiri, Konda Amarnath
Diffuse Large B Cell Lymphomas (DLBCL) encompasses a heterogeneous group of tumors that together constitute the commonest of all Non Hodgkin Lymphoma (NHL) and the proclivity of DLBCL to oral cavity is unknown. They mostly arise from soft tissues as asymptomatic lesions, mostly without 'B' symptoms and involvement of jaw bones is uncommon. Most studies and case reports of oral DLBCL's are based on, manifestation of primary extra-nodal disease or a component of a disseminated disease process involving regional lymph nodes...
April 2016: Journal of Clinical and Diagnostic Research: JCDR
Wojciech Jurczak, Agata Hanna Bryk, Patrycja Mensah, Krystyna Gałązka, Małgorzata Trofimiuk-Müldner, Łukasz Wyrobek, Anna Sawiec, Aleksander B Skotnicki
BACKGROUND: Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin's lymphoma. Standard first-line treatment for this aggressive subtype comprises the anti-CD20 antibody rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. If patients receiving such treatment have an early relapse, or their disease is initially refractory to such treatment, standard salvage regimens may not be effective. There is therefore a high unmet clinical need for new targeted agents that might improve the outcome for such patients...
2016: Journal of Medical Case Reports
Viola Maria Popov, Camelia Marioara Dobrea, Mihai Popescu, Iancu Emil Pleşea, Valentin Titus Grigorean, Ruxandra Diana Sinescu, Victor Dan Eugen Strâmbu
UNLABELLED: Diffuse large B-cell lymphoma (DLBCL) represent the most frequently non-Hodgkin's lymphoma (NHL) (over 30%), especially in developing countries. Many associations of NHL with another neoplasia were described following chemotherapy or radiotherapy regimens. The coexistence of DLBCL with myeloproliferative neoplasms (MPNs) JAK2V617F positive at the onset was very rare reported in the literature. We describe a clinical case of a 52-year-old man who presented both diagnoses at the onset - DLBCL and MPN - polycythemia vera (PV) type...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
Andi K Cani, Moaaz Soliman, Daniel H Hovelson, Chia-Jen Liu, Andrew S McDaniel, Michaela J Haller, Jarred V Bratley, Samantha E Rahrig, Qiang Li, César A Briceño, Scott A Tomlins, Rajesh C Rao
Non-Hodgkin lymphoma of the orbit and ocular adnexa is the most common primary orbital malignancy. Treatments for low- (extra-nodal marginal zone and follicular lymphomas) and high-grade (diffuse large B-cell lymphoma) are associated with local and vision-threatening toxicities. High-grade lymphomas relapse frequently and exhibit poor survival rates. Despite advances in genomic profiling and precision medicine, orbital and ocular adnexal lymphomas remain poorly characterized molecularly. We performed targeted next-generation sequencing (NGS) profiling of 38 formalin-fixed, paraffin-embedded orbital and ocular adnexal lymphomas obtained from a single-center using a panel targeting near-term, clinically relevant genes...
July 2016: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
David Belada, Pencho Georgiev, Shaker Dakhil, Lowell F Inhorn, David Andorsky, J Thaddeus Beck, Donald Quick, Ruth Pettengell, Robert Daly, James P Dean, Mariya Pavlyuk, Nelly Failloux, Kai Hübel
UNLABELLED: We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv...
August 2016: Future Oncology
Tomoo Osumi, Tetsuya Mori, Yoko Shioda, Chikako Kiyotani, Keita Terashima, Motohiro Kato, Daisuke Tomizawa, Kentaro Ohki, Nobutaka Kiyokawa, Hideto Iwafuchi, Takako Yoshioka, Atsuko Nakazawa, Kimikazu Matsumoto
BACKGROUND: LMB chemotherapy based on the FAB LMB96 study is internationally accepted as one of the standard treatments for pediatric B-cell non-Hodgkin lymphoma (B-NHL), though experience with this regimen in Japan is very limited. Since 2009, we have administered LMB chemotherapy to children with B-NHL at the National Center for Child Health and Development. Thus, we herein report the clinical characteristics and outcomes of 13 children with B-NHL given LMB chemotherapy. RESULTS: Median age was 7...
March 2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Tarik Hadid, Ali Raufi, Zyad Kafri, Mary Mandziara, John Kalabat, Susan Szpunar, Kleanthe Kolizeras, Mary Steigelman, Ayad Al-Katib
INTRODUCTION: Radioimmunotherapy (RIT) is a unique therapeutic modality that combines biologic and radiolytic mechanisms to induce tumor kill. RIT is underutilized in the community outpatient setting. METHODS: This is an institutional review of patients treated with RIT at St. John Hospital and Medical Center (SJH&MC) 2003-2011. RIT agents were dosed according to recommended guidelines. Response was assessed using the Revised Response Criteria for Malignant Lymphoma and toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events...
April 2016: Nuclear Medicine and Biology
Divya Supari, Anuradha Ananthamurthy
The aim of this study was to assess the distribution of nodal follicular lymphomas (FL) among various subtypes of non- Hodgkin lymphoma and to study their clinico-pathological features. Clinical details, histomorphology including grading & patterns and immunoprofile of 44 cases were studied. Majority of the cases were grade 1 (61 %) FL. BCL2 positivity was higher in low grade FLs (97 %). An associated diffuse large B cell lymphoma component was seen in 18 % and was present only in conjunction with grade 3 FL...
June 2016: Indian Journal of Hematology & Blood Transfusion
Abdul Shukkur Ebrahim, Hussam Sabbagh, Allison Liddane, Ali Raufi, Mustapha Kandouz, Ayad Al-Katib
INTRODUCTION: BCL-2 is the founding member of the BCL-2 family of apoptosis regulatory proteins that either induce (pro-apoptotic) or inhibit (anti-apoptotic) apoptosis. The anti-apoptotic BCL-2 is classified as an oncogene, as damage to the BCL-2 gene has been shown to cause a number of cancers, including lymphoma. Ongoing research has demonstrated that disruption of BCL-2 leads to cell death. BCL-2 is also known to be involved in the development of resistance to chemotherapeutic agents, further underscoring the importance of targeting the BCL-2 gene in cancer therapeutics...
September 2016: Journal of Cancer Research and Clinical Oncology
Jae-Cheol Jo, Jin Ho Baek, Je-Hwan Lee, Young-Don Joo, Sung-Hwa Bae, Jung-Lim Lee, Jung-Hee Lee, Dae-Young Kim, Won-Sik Lee, Hun Mo Ryoo, Yunsuk Choi, Hawk Kim, Kyoo-Hyung Lee
AIM: We performed a phase II study to evaluate the efficacy of combination chemotherapy consisting of gemcitabine, dexamethasone and oxaliplatin (GemDOx) as a biweekly regimen and salvage therapy in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). METHODS: Gemcitabine (1000 mg/m(2) ) and oxaliplatin (85 mg/m(2) ) were administered intravenously on days 1 and 15, and dexamethasone (40 mg) was administered orally on days 1-4. RESULTS: Twenty-nine patients were enrolled, and most patients had diffuse large B-cell lymphoma (n = 18)...
June 2016: Asia-Pacific Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"